Avanos Medical (AVNS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Annual Meeting of Stockholders, originally set for April 21, 2026, has been postponed due to a pending merger announced on April 14, 2026.
Voting matters and shareholder proposals
No voting will occur as the annual meeting has been postponed in connection with the pending merger.
Shareholder rights and capital structure
Postponement of the annual meeting may impact the timing of shareholder votes and related governance actions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Avanos Medical
- Acquisition by AIP brings $25/share payout and accelerates growth as company goes private.AVNS
Proxy filing5 May 2026 - Q1 2026 sales up 8.8% to $182.2M with strong nutrition growth and $1.27B acquisition deal.AVNSQ1 20265 May 2026
- Shareholders to vote on Avanos Medical's acquisition by AIP, focusing on innovation and growth.AVNSProxy filing23 Apr 2026
- Avanos to be acquired by AIP for $1.272B, going private with $25/share payout to shareholders.AVNSProxy filing14 Apr 2026
- Strategic growth, innovation, and M&A drive a $1B revenue vision by 2030.AVNS44th Annual J.P. Morgan Healthcare Conference13 Apr 2026
- Key votes include director elections, auditor ratification, and incentive plan amendment.AVNSProxy Filing12 Mar 2026
- Proxy covers director elections, pay, auditor ratification, and ESG progress, with all proposals supported.AVNSProxy Filing12 Mar 2026
- Focused on core growth, tariff mitigation, and innovation to drive strong financial performance.AVNSThe Citizens Life Sciences Conference 202611 Mar 2026
- FY25 net sales hit $701M; 2026 targets $700–$720M sales and $0.90–$1.10 EPS.AVNSQ4 202524 Feb 2026